Laboratory diagnosis of the thrombophilic state in cancer patients.

摘要: Perturbations of coagulation in cancer patients have been described for a long time. In up to 90% "routine" blood tests are abnormal leading hypercoagulable state these patients. Among an increase clotting factors, fibrinogen, fibrinogen/fibrin degradation products, and thrombocytosis. Markers the activation developed, levels FPA, F1+2, TAT, D-Dimer found higher More specific procoagulant activities (CP TF) also can be measured but none them any predictive value occurrence venous thromboembolism Consistent with this is finding that most reduced plasma inhibitors coagulation. These complex abnormalities clinically expressed as thrombosis, low-grade or fulminant DIC which assessed by different laboratory tests, hemorrhage when fibrinolysis system impaired. However, no studies shown date relationship between clinical expression single individual. Because at high risk thrombosis special conditions such surgery during chemotherapy, prophylaxis various forms heparin recommended.